{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:45:46Z","timestamp":1785883546021,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,10]],"date-time":"2027-06-10T00:00:00Z","timestamp":1812585600000},"content-version":"am","delay-in-days":282,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T35DK104689"],"award-info":[{"award-number":["T35DK104689"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.avsg.2026.04.067","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:42:56Z","timestamp":1779259376000},"page":"415-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sodium Glucose Cotransporter-2 Inhibitors are Not Associated with Amputation After Lower Extremity Revascularization in Patients with Diabetes"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-1342","authenticated-orcid":false,"given":"Uma D.","family":"Alappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin K.","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Alameddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassius Iyad","family":"Ochoa Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2026.04.067_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIR.0000000000001153","article-title":"Health disparities in peripheral artery disease: a scientific statement from the American Heart Association","volume":"148","author":"Allison","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.067_bib2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.avsg.2026.04.067_bib3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/CIRCRESAHA.121.318261","article-title":"Advances in revascularization for peripheral artery disease: revascularization in PAD","volume":"128","author":"Beckman","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.avsg.2026.04.067_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1148040","article-title":"Diabetes mellitus in peripheral artery disease: beyond a risk factor","volume":"10","author":"Singh","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib9","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.avsg.2026.04.067_bib10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.118.033810","article-title":"Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.067_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12933-022-01627-0","article-title":"Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"21","author":"Zhu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.avsg.2026.04.067_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.067_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ehjcvp\/pvad004","article-title":"Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors","volume":"9","author":"Lee","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.avsg.2026.04.067_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.avsg.2026.04.067_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2026.04.067_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.avsg.2026.04.067_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.avsg.2026.04.067_bib24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort Study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.067_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12933-023-01992-4","article-title":"Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease","volume":"22","author":"Takahara","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.avsg.2026.04.067_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13098-023-00982-6","article-title":"Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"15","author":"Lee","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.avsg.2026.04.067_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc24-1546","article-title":"Use of SGLT2i versus DPP-4i as an add-on therapy and the risk of PAD-Related surgical events (Amputation, stent placement, or vascular surgery): a cohort study in veterans with diabetes","volume":"48","author":"Griffin","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.avsg.2026.04.067_bib30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2022.08.772","article-title":"Cardiovascular effects of Canagliflozin in relation to renal function and albuminuria","volume":"80","author":"Sarraju","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2026.04.067_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2026.04.067_bib32","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2026.04.067_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2026.04.067_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.avsg.2026.04.067_bib36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejvs.2021.09.031","article-title":"Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis","volume":"62","author":"Rodionov","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2026.04.067_bib37","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.avsg.2026.04.067_bib38","article-title":"Should we be concerned about SGLT-2 inhibitors worsening peripheral artery disease?","author":"Weisman","year":"2025","journal-title":"NEJM J Watch"},{"key":"10.1016\/j.avsg.2026.04.067_bib39","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1111\/dom.15901","article-title":"A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations","volume":"26","author":"Geng","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2026.04.067_bib40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626003808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626003808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:56:25Z","timestamp":1785880585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509626003808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0890509626003808"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2026.04.067","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Cotransporter-2 Inhibitors are Not Associated with Amputation After Lower Extremity Revascularization in Patients with Diabetes","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2026.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}